EU/3/16/1820

About

On 12 January 2017, orphan designation (EU/3/16/1820) was granted by the European Commission to Centre Hospitalier Universitaire d'Angers, France, for hydroxychloroquine for the treatment of antiphospholipid syndrome.

The sponsorship was transferred to Crisitina Belizna, France, in November 2020.

Key facts

Active substance
Hydroxychloroquine
Medicine name
-
Disease / condition
Treatment of antiphospholipid syndrome
Date of first decision
12/01/2017
Outcome
Positive
EU designation number
EU/3/16/1820

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Cristina Belizna
12 Boulevard Albert Camus  
49100 Angers  
France 
Email: cristina.belizna@wanadoo.fr

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating
Average
1 rating